Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin’s Disease Receiving ABVD Chemotherapy

INCLUSION:

Previously untreated Hodgkin's disease patients who are scheduled to receive standard ABVD chemo.
Histologically proven diagnosis of Hodgkin's disease of any type.
Bidimensionally measurable disease.
Signed informed consent.
Age >/= 16 yrs.
Adequate bone marrow reserve (ANC>1000/uL, Platelet >100,000/uL.
LVEF>/=50% by MUGA scan or echocardiogram.
Serum creatinine <2mg/dL; serum bilirubin<2mg/dL.

EXCLUSION:

HIV positive.
Pregnant women and those of child bearing age who are not using adequate contraception.
Prior chemotherapy.
Severe pulmonary disease including COPD and asthma.
History of prior sensitivity to E.coli derived products.